Report Detail

Pharmaceuticals & Healthcare Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2018

  • RnM2252265
  • |
  • 12 July, 2018
  • |
  • Global
  • |
  • 91 pages
  • |
  • Global Markets Direct
  • |
  • Pharmaceuticals & Healthcare

Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2018

Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Overview

              Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Products under Development by Companies

                      Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Therapeutics Assessment

                        Assessment by Target

                          Assessment by Mechanism of Action

                            Assessment by Route of Administration

                              Assessment by Molecule Type

                                Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Companies Involved in Therapeutics Development

                                  Achillion Pharmaceuticals Inc

                                    Akari Therapeutics Plc

                                      Alexion Pharmaceuticals Inc

                                        Alnylam Pharmaceuticals Inc

                                          Amgen Inc

                                            ChemoCentryx Inc

                                              greenovation Biotech GmbH

                                                Omeros Corp

                                                  Ra Pharmaceuticals Inc

                                                    Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Drug Profiles

                                                      ACH-4471 - Drug Profile

                                                        Product Description

                                                          Mechanism Of Action

                                                            R&D Progress

                                                              avacopan - Drug Profile

                                                                Product Description

                                                                  Mechanism Of Action

                                                                    R&D Progress

                                                                      cemdisiran - Drug Profile

                                                                        Product Description

                                                                          Mechanism Of Action

                                                                            R&D Progress

                                                                              Coversin - Drug Profile

                                                                                Product Description

                                                                                  Mechanism Of Action

                                                                                    R&D Progress

                                                                                      eculizumab biosimilar - Drug Profile

                                                                                        Product Description

                                                                                          Mechanism Of Action

                                                                                            R&D Progress

                                                                                              Gene Therapy for Age-Related Macular Degeneration, Atypical Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile

                                                                                                Product Description

                                                                                                  Mechanism Of Action

                                                                                                    R&D Progress

                                                                                                      GRN-003 - Drug Profile

                                                                                                        Product Description

                                                                                                          Mechanism Of Action

                                                                                                            R&D Progress

                                                                                                              OMS-721 - Drug Profile

                                                                                                                Product Description

                                                                                                                  Mechanism Of Action

                                                                                                                    R&D Progress

                                                                                                                      RA-101495 - Drug Profile

                                                                                                                        Product Description

                                                                                                                          Mechanism Of Action

                                                                                                                            R&D Progress

                                                                                                                              ravulizumab - Drug Profile

                                                                                                                                Product Description

                                                                                                                                  Mechanism Of Action

                                                                                                                                    R&D Progress

                                                                                                                                      ravulizumab next generation - Drug Profile

                                                                                                                                        Product Description

                                                                                                                                          Mechanism Of Action

                                                                                                                                            R&D Progress

                                                                                                                                              Small Molecules to Inhibit MASP2 for Immunology - Drug Profile

                                                                                                                                                Product Description

                                                                                                                                                  Mechanism Of Action

                                                                                                                                                    R&D Progress

                                                                                                                                                      Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Dormant Projects

                                                                                                                                                        Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Product Development Milestones

                                                                                                                                                          Featured News & Press Releases

                                                                                                                                                            Apr 26, 2018: FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

                                                                                                                                                              Jan 08, 2018: Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment

                                                                                                                                                                Jan 03, 2018: Omeros Reaches Agreement with FDA on OMS721 Phase 3 Trial Protocol for IgA Nephropathy

                                                                                                                                                                  Oct 16, 2017: Omeros Announces Upcoming Presentation of Clinical OMS721 Data at European Society for Blood and Marrow Transplantation

                                                                                                                                                                    Sep 26, 2017: Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS)

                                                                                                                                                                      Mar 27, 2017: Omeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome at World Congress of Nephrology

                                                                                                                                                                        Oct 27, 2016: Alexion Initiates Simultaneous Registration Trials of ALXN1210 for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)

                                                                                                                                                                          Oct 17, 2016: ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome at ASN Kidney Week 2016

                                                                                                                                                                            Sep 06, 2016: Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop

                                                                                                                                                                              Jul 28, 2016: Omeros Confirms OMS721 Phase 3 Development Plan with European Medicines Agency

                                                                                                                                                                                May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress

                                                                                                                                                                                  Mar 08, 2016: Omeros Initiates its Phase 3 Program for OMS721 in aHUS Following Meeting with FDA

                                                                                                                                                                                    Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial

                                                                                                                                                                                      Jan 05, 2016: Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays

                                                                                                                                                                                        Dec 07, 2015: Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting

                                                                                                                                                                                          Appendix

                                                                                                                                                                                            Methodology

                                                                                                                                                                                              Coverage

                                                                                                                                                                                                Secondary Research

                                                                                                                                                                                                  Primary Research

                                                                                                                                                                                                    Expert Panel Validation

                                                                                                                                                                                                      Contact Us

                                                                                                                                                                                                        Disclaimer

                                                                                                                                                                                                        Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2018

                                                                                                                                                                                                        Summary

                                                                                                                                                                                                        Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atypical Hemolytic Uremic Syndrome - Pipeline Review, H2 2018, provides an overview of the Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline landscape.

                                                                                                                                                                                                        Atypical hemolytic uremic syndrome is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. Symptoms include vomiting, abdominal pain, pale skin tone, fatigue and irritability, blood in the urine and confusion.

                                                                                                                                                                                                        Report Highlights

                                                                                                                                                                                                        Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atypical Hemolytic Uremic Syndrome - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Atypical Hemolytic Uremic Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

                                                                                                                                                                                                        The Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 3 and 4 respectively.

                                                                                                                                                                                                        Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

                                                                                                                                                                                                        Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

                                                                                                                                                                                                        Scope

                                                                                                                                                                                                        - The pipeline guide provides a snapshot of the global therapeutic landscape of Atypical Hemolytic Uremic Syndrome (Gastrointestinal).
                                                                                                                                                                                                        - The pipeline guide reviews pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
                                                                                                                                                                                                        - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
                                                                                                                                                                                                        - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
                                                                                                                                                                                                        - The pipeline guide reviews key companies involved in Atypical Hemolytic Uremic Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
                                                                                                                                                                                                        - The pipeline guide evaluates Atypical Hemolytic Uremic Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
                                                                                                                                                                                                        - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
                                                                                                                                                                                                        - The pipeline guide reviews latest news related to pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Gastrointestinal)

                                                                                                                                                                                                        Reasons to buy

                                                                                                                                                                                                        - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
                                                                                                                                                                                                        - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
                                                                                                                                                                                                        - Find and recognize significant and varied types of therapeutics under development for Atypical Hemolytic Uremic Syndrome (Gastrointestinal).
                                                                                                                                                                                                        - Classify potential new clients or partners in the target demographic.
                                                                                                                                                                                                        - Develop tactical initiatives by understanding the focus areas of leading companies.
                                                                                                                                                                                                        - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
                                                                                                                                                                                                        - Formulate corrective measures for pipeline projects by understanding Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
                                                                                                                                                                                                        - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
                                                                                                                                                                                                        - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


                                                                                                                                                                                                        Summary:
                                                                                                                                                                                                        Get latest Market Research Reports on Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome). Industry analysis & Market Report on Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) is a syndicated market report, published as Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2018. It is complete Research Study and Industry Analysis of Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


                                                                                                                                                                                                        REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                                                                        Purchase this Report

                                                                                                                                                                                                        $2,000.00
                                                                                                                                                                                                        $4,000.00
                                                                                                                                                                                                        $6,000.00
                                                                                                                                                                                                        1,602.69
                                                                                                                                                                                                        3,205.38
                                                                                                                                                                                                        4,808.07
                                                                                                                                                                                                        1,783.25
                                                                                                                                                                                                        3,566.51
                                                                                                                                                                                                        5,349.76
                                                                                                                                                                                                        215,720.00
                                                                                                                                                                                                        431,440.00
                                                                                                                                                                                                        647,160.00
                                                                                                                                                                                                        137,792.80
                                                                                                                                                                                                        275,585.60
                                                                                                                                                                                                        413,378.40
                                                                                                                                                                                                        Credit card Logo

                                                                                                                                                                                                        Related Reports


                                                                                                                                                                                                        Reason to Buy

                                                                                                                                                                                                        Request for Sample of this report